# Shanghai Jeyou Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-jeyou-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.jeyoupharma.com
- Total disclosed funding: $286M
- Latest round: Series A (Jan 8, 2026)
- Investors on record: 5

## About

Shanghai Jeyou Pharmaceutical Co., Ltd. is a pharmaceutical company based in China, focused on developing and distributing innovative prescription medications that cater to various medical needs.Founded in 2018, Shanghai Jeyou Pharmaceutical Co., Ltd. operates from its headquarters in Shanghai, China. The company specializes in pharmaceutical development and has completed 1 deal with its most recent Series A funding round occurring on January 8, 2026, raising CNY 2 billion from investors including GTJA Innovation Investment and Geuniom Group.Jeyou Pharma specializes in the development and distribution of innovative pharmaceutical products aimed at addressing various medical needs. Their core offerings include a range of prescription medications designed to target chronic conditions and enhance patient outcomes. These products are formulated to provide effective treatment solutions, with an emphasis on quality and safety. The company caters to healthcare providers, hospitals, and pharmacies as their primary customer base, with end users including patients who rely on these medications for their health management. Jeyou Pharma's market reach extends into North America and parts of Europe, where they have established partnerships with local distributors to ensure accessibility and compliance with regional healthcare regulations.Jeyou Pharma generates revenue primarily through direct sales of its pharmaceutical products to healthcare institutions and retailers. The transaction structure involves B2B sales where hospitals and pharmacies place bulk orders based on their inventory needs and patient demand. This transactional model allows for streamlined operations and efficient supply chain management, maximizing product availability. Pricing strategies are based on competitive market analyses and are tailored to meet the specific needs of different customer segments. The company's flagship products are positioned within the market at premium price points, reflecting their commitment to quality and effectiveness in treating targeted health conditions. Revenue is further supported by ongoing partnerships with healthcare providers who may require regular replenishment of pharmaceutical supplies.In January 2026, Shanghai Jeyou Pharmaceutical Co., Ltd. raised approximately CNY 2 billion in Series A funding. This funding will be primarily used for the development of the company's core business. The company aims to launch new pharmaceutical products in the near future, expanding its offerings to meet additional healthcare needs. Additionally, Jeyou Pharma plans to enter new markets in Asia and Europe by 2027 to broaden its reach and customer base.

## Funding rounds

- Series A, Jan 8, 2026, $286M — New Alliance Capital, Real Power Capital, GTJA Innovation Investment, Jinkong Qiyuan Capital, Geuniom Group

## Investors

- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A
- Real Power Capital (https://capitalatlas.ai/funds/real-power-capital) — Series A
- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series A
- Geuniom Group — Series A